Business Context and Reporting Period
This Form 8-K is filed by PharmAthene, Inc. (not Altimmune, Inc.) on April 7, 2010. The report details the entry into material definitive agreements regarding a registered offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Size: 1,666,668 shares of common stock and warrants to purchase up to 500,000 additional shares.
- Offering Price: $1.50 per share.
- Gross Proceeds: Approximately $2.5 million (before fees and expenses).
- Placement Agent Fees: 7.0% of gross proceeds, estimated at $175,000.
- Expense Reimbursement: Up to the lesser of $25,000 or 8% of gross proceeds less fees.
- Warrant Terms: Exercisable 6 months after issuance at $1.89 per share; 5-year term.
Material Changes and Agreements
The Company entered into a Placement Agency Agreement with Roth Capital Partners, LLC and a Securities Purchase Agreement with an institutional investor. Key contractual terms include:
- Sale Restriction: The Company is limited from selling common stock or convertible securities below the offering price for 45 days post-offering.
- Participation Rights: Investors are granted rights to participate in additional offerings for one year.
- Regulatory Filing: Shares are issued pursuant to a prospectus supplement filed under a shelf registration statement (Form S-3) declared effective on February 12, 2009.
Outlook, Risks, and Management Commentary
The filing does not provide specific financial guidance, revenue outlook, or management commentary on operational performance. The primary focus is the execution of the capital raise. The text notes that the agreements contain customary representations and warranties but explicitly states these are not intended as factual disclosures of the Company's current state of affairs for the general public.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds received after deducting all fees and expenses.
- Confirm the identity of the institutional investor and any potential conflicts of interest.
- Review the full text of the Placement Agency Agreement (Exhibit 1.1) and Securities Purchase Agreement (Exhibit 10.1) for specific covenants.
- Monitor the Company's cash position to assess the runway provided by the $2.5 million gross proceeds.
- Check for any subsequent filings regarding the exercise of warrants or additional capital raises within the 45-day lock-up period.